Advanced

Predictive factors in pancreatic ductal adenocarcinoma: Role of the inflammatory response.

Tingstedt, Bobby LU ; Johansson, Patrik; Andersson, Bodil LU and Andersson, Roland LU (2007) In Scandinavian Journal of Gastroenterology 42(6). p.754-759
Abstract
Objective. Pancreatic ductal adenocarcinoma is a highly lethal disease and most patients are not eligible for curable resection. Estimation of prognosis is essential in order to provide the best individual treatment for patients with pancreatic adenocarcinoma. Prediction of survival by current methods is limited, therefore the objective of this study was to determine possible prognostic factors identified at the time of diagnosis. Material and methods. All 119 consecutive patients with pancreatic ductal adenocarcinoma receiving palliative treatment at the Department of Surgery, Lund University Hospital from 1999 through 2002 were reviewed retrospectively. Prognostic factors and interventions were analysed statistically. C- reactive protein... (More)
Objective. Pancreatic ductal adenocarcinoma is a highly lethal disease and most patients are not eligible for curable resection. Estimation of prognosis is essential in order to provide the best individual treatment for patients with pancreatic adenocarcinoma. Prediction of survival by current methods is limited, therefore the objective of this study was to determine possible prognostic factors identified at the time of diagnosis. Material and methods. All 119 consecutive patients with pancreatic ductal adenocarcinoma receiving palliative treatment at the Department of Surgery, Lund University Hospital from 1999 through 2002 were reviewed retrospectively. Prognostic factors and interventions were analysed statistically. C- reactive protein ( CRP) at the time of diagnosis was measured in 109 patients. Results. The overall median survival was 4.4 months. By means of a multivariate analysis it was shown that CRP ( p < 0.001) and tumour size ( p < 0.018) were independent predictors of survival. The median survival of patients with normal CRP at the time of diagnosis was 10.8 months versus 4.2 months for those with raised CRP levels (>= 5 mg/l; p < 0.001). Chemotherapy was the only intervention associated with a longer survival time ( p < 0.001 versus no chemotherapy). Conclusions. The poor prognosis for patients with pancreatic ductal adenocarcinoma was confirmed. CRP proved to be a strong independent predictor of survival. Together with previous reported factors, CRP could serve as a potential tool to determine future treatment strategies for optimal individual palliation. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
CRP, prognostic factor, pancreatic ductal adenocarcinoma, survival
in
Scandinavian Journal of Gastroenterology
volume
42
issue
6
pages
754 - 759
publisher
Taylor & Francis
external identifiers
  • wos:000246766600012
  • scopus:34248579658
ISSN
1502-7708
DOI
10.1080/00365520601058452
language
English
LU publication?
yes
id
fd70a897-1d52-46c0-b68f-b0bc683a526d (old id 168270)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17505998&dopt=Abstract
date added to LUP
2007-07-24 11:27:21
date last changed
2017-01-01 07:18:43
@article{fd70a897-1d52-46c0-b68f-b0bc683a526d,
  abstract     = {Objective. Pancreatic ductal adenocarcinoma is a highly lethal disease and most patients are not eligible for curable resection. Estimation of prognosis is essential in order to provide the best individual treatment for patients with pancreatic adenocarcinoma. Prediction of survival by current methods is limited, therefore the objective of this study was to determine possible prognostic factors identified at the time of diagnosis. Material and methods. All 119 consecutive patients with pancreatic ductal adenocarcinoma receiving palliative treatment at the Department of Surgery, Lund University Hospital from 1999 through 2002 were reviewed retrospectively. Prognostic factors and interventions were analysed statistically. C- reactive protein ( CRP) at the time of diagnosis was measured in 109 patients. Results. The overall median survival was 4.4 months. By means of a multivariate analysis it was shown that CRP ( p &lt; 0.001) and tumour size ( p &lt; 0.018) were independent predictors of survival. The median survival of patients with normal CRP at the time of diagnosis was 10.8 months versus 4.2 months for those with raised CRP levels (&gt;= 5 mg/l; p &lt; 0.001). Chemotherapy was the only intervention associated with a longer survival time ( p &lt; 0.001 versus no chemotherapy). Conclusions. The poor prognosis for patients with pancreatic ductal adenocarcinoma was confirmed. CRP proved to be a strong independent predictor of survival. Together with previous reported factors, CRP could serve as a potential tool to determine future treatment strategies for optimal individual palliation.},
  author       = {Tingstedt, Bobby and Johansson, Patrik and Andersson, Bodil and Andersson, Roland},
  issn         = {1502-7708},
  keyword      = {CRP,prognostic factor,pancreatic ductal adenocarcinoma,survival},
  language     = {eng},
  number       = {6},
  pages        = {754--759},
  publisher    = {Taylor & Francis},
  series       = {Scandinavian Journal of Gastroenterology},
  title        = {Predictive factors in pancreatic ductal adenocarcinoma: Role of the inflammatory response.},
  url          = {http://dx.doi.org/10.1080/00365520601058452},
  volume       = {42},
  year         = {2007},
}